|Dr. Arthur O. Tzianabos||Pres, CEO & Director||845.78k||N/A||1963|
|Mr. W. Bradford Smith||CFO, Treasurer & Sec.||552.76k||N/A||1956|
|Dr. Albert Seymour Ph.D.||Chief Scientific Officer||581.07k||N/A||1968|
|Dr. Saswati Chatterjee||Co-Founder & Chair of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Timothy P. Kelly||Chief Technical Operations Officer||N/A||N/A||1969|
|Dr. Paul Alloway J.D., Ph.D.||Sr. VP & Gen. Counsel||N/A||N/A||N/A|
|Ms. Theresa McNeely||Chief Communications Officer & Patient Advocate||N/A||N/A||1964|
|Ms. Melissa Gelormini||VP of HR||N/A||N/A||N/A|
|Dr. Gabriel M. Cohn M.B.A., M.D.||Chief Medical Officer||N/A||N/A||1959|
|Mr. Michael Blum M.B.A.||Sr. VP of Commercial||N/A||N/A||N/A|
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Homology Medicines, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 8.